Factual data · GO/NO-GO verdict · Financial model calibrated over 96 months
In Lille, pharmacy valuation is 80-110 % of revenue (90 % average), with a regulated gross margin of 26-32 %. New creation is extremely rare (transfer/merger only).
Dominant profile: business · etudiante
Competitive density: high (dense supply, segmentation required).
Dominant players: regulated public-insurance sector, few private chains.
Positioning recommendation: Competitive positioning required: sector margin is tight, edge comes from operational efficiency.
| Indicator | Year 1 | Year 2 | Year 3 |
|---|---|---|---|
| Year 1 revenue | 1.5M € → 4.5M € | ×1,18 (ramp-up) | ×1,32 (steady-state) |
| Target net margin | negative to low | 4 % | 10 % |
| Working capital (days of revenue) | 45-60 d | 35-50 d | 30-45 d |
| Cumulative ROI | investment | ~50 % | Payback at 96 months |
These ratios are calibrated on MarketLens sector benchmarks and adjusted by local coefficients of Lille (cost national average, income national average).
MarketLens combines AI market study, business plan calibrated for 24 countries, and post-launch monitoring. Everything exportable to PDF, PowerPoint, Excel and Word.